Post by Nadica (She/Her) on Nov 6, 2024 3:40:21 GMT
Blood transcriptomic analyses do not support SARS-CoV-2 persistence in patients with post-COVID-19 condition with chronic fatigue syndrome - Published Oct 25, 2024
Post-COVID-19 condition (also known as long COVID) represents a crucial and emerging global public health challenge. Intriguingly, growing claims exist about the persistence of SARS-CoV-2 or viral antigens in the blood and tissues of patients with long COVID for months after the acute infection. This occurrence is not exclusive to SARS-CoV-2 as long-term shedding of influenza A virus in the stool of immunocompromised patients has been reported previously.1 Furthermore, this finding corresponds with that of a previous report that at 2 months following acute COVID-19, viral RNA was detected in various solid tissues and peripheral blood of immunocompromised individuals with post-COVID-19 symptoms, as opposed to that in immunocompetent individuals.2 Further in-depth studies are warranted to investigate the different aspects of a SARS-CoV-2 reservoir or persistent viral presence in long COVID. Viraemia is not a common outcome of COVID-19, occurring in approximately 1% of severe cases. Overall, the majority of studies3 conducted during the acute phase of COVID-19 show the presence of detectable RNA in few blood samples, frequently characterised by low copy numbers and replication-incompetent viruses. (Read full text at link!)
Post-COVID-19 condition (also known as long COVID) represents a crucial and emerging global public health challenge. Intriguingly, growing claims exist about the persistence of SARS-CoV-2 or viral antigens in the blood and tissues of patients with long COVID for months after the acute infection. This occurrence is not exclusive to SARS-CoV-2 as long-term shedding of influenza A virus in the stool of immunocompromised patients has been reported previously.1 Furthermore, this finding corresponds with that of a previous report that at 2 months following acute COVID-19, viral RNA was detected in various solid tissues and peripheral blood of immunocompromised individuals with post-COVID-19 symptoms, as opposed to that in immunocompetent individuals.2 Further in-depth studies are warranted to investigate the different aspects of a SARS-CoV-2 reservoir or persistent viral presence in long COVID. Viraemia is not a common outcome of COVID-19, occurring in approximately 1% of severe cases. Overall, the majority of studies3 conducted during the acute phase of COVID-19 show the presence of detectable RNA in few blood samples, frequently characterised by low copy numbers and replication-incompetent viruses. (Read full text at link!)